Skip to main content
Contact Us
Subscribe
E-Edition
72°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Purple Biotech Ltd ADR
(NQ:
PPBT
)
0.4000
+0.0200 (+5.26%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Purple Biotech Ltd ADR
< Previous
1
2
3
Next >
Purple Biotech Fortifies NT219 Patent Protection
November 02, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
October 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Purple Biotech Announces $5 Million Registered Direct Offering
October 17, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech: Q1 Earnings Insights
May 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
October 13, 2023
Via
Benzinga
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
September 21, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Second Quarter 2023 Financial Results
August 22, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
July 31, 2023
On Monday, 27 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 27, 2023
During Thursday, 56 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 12, 2023
Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
Via
Benzinga
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Debuts Scientific Advisory Board
April 25, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
April 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
April 18, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
March 24, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
March 16, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
February 14, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
February 02, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 01, 2023
Via
Benzinga
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
January 03, 2023
As a subsidiary of Clalit Healthcare Services, Israel’s largest HMO, Mor Research Applications brings Purple Biotech first access to research conducted at 14 hospitals The collaboration with Mor...
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
November 15, 2022
From
Purple Biotech Ltd.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
December 08, 2022
During Thursday's trading, 138 companies set new 52-week lows.
Via
Benzinga
Purple Biotech to Present at the Jefferies London Healthcare Conference
November 10, 2022
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
November 02, 2022
From
Purple Biotech Ltd.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.